Detailed Phase II T-DM1 Breast Cancer Data Boost ImmunoGen
By Jennifer Boggs
Tuesday, September 27, 2011
ImmunoGen Inc. and partner Roche AG reported positive top-line data earlier this year from a Phase II trial testing T-DM1 in HER2-positive metastatic breast cancer patients, but observers had been waiting for the detailed progression-free survival (PFS) numbers. They got those figures Sunday during a presentation at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.